Skip to content

A randomized controlled trial of neoadjuvant chemotherapy in patients with locally advanced cervical cancer in southern Xinjiang

A randomized controlled trial of neoadjuvant chemotherapy in patients with locally advanced cervical cancer in southern Xinjiang

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057766
Enrollment
Unknown
Registered
2022-03-17
Start date
2022-03-16
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

Group 1:neoadjuvant chemotherapy followed by surgery
Group 2:abdominal radical hysterectomy + pelvic lymphadenectomy ± para-aortic lymphadenectomy

Sponsors

The First People's Hospital of Kashgar
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Uygur women aged 18-65 years; 2. Newly treated patients with cervical cancer; 3. Clinical diagnosis of cervical cancer stage IB3 or IIA2 (FIGO stage, 2018); 4. MRI examination confirmed no distant metastasis, no obvious bladder and rectal invasion; 5. Pathological diagnosis of cervical squamous cell carcinoma, adenocarcinoma or adenocarcinoma; 6. Expected survival of more than 3 months; 7. PS score 0-1.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors; 2. MRI indicated that the short diameter of pelvic and abdominal lymph nodes was greater than 10mm; 3. Patients with a history of myocardial infarction or stroke, or unstable angina, decompensated heart failure, or deep vein thrombosis; 4. Liver insufficiency (aspartate/alanine aminotransferase >2.5 times the upper limit of the standard); 5. Renal insufficiency (serum muscle liver >2 times the standard upper limit); 6. A history of chronic lung disease with restrictive respiratory dysfunction; 7. History of transplantation of important organs and immune diseases; 8. History of severe mental illness and brain dysfunction; 9. A history of drug abuse or use; 10. Unable or unwilling to sign informed consent or comply with study requirements; 11. Patients during pregnancy and perinatal period.

Design outcomes

Primary

MeasureTime frame
progression-free survival;

Secondary

MeasureTime frame
overall survival;the need for adjuvant radiotherapy;economic benefit ratio;incidence of recent adverse reactions;incidence of long-term side effects;quality of life;

Countries

China

Contacts

Public ContactWan Yingxiang

The First People's Hospital of Kashgar

1801562401@qq.com+86 18399612977

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026